Pat PurcellMeeting Engagement
Bud BilanichSuccess Coach
Matthew DurhamOmnidynamic Marketing
Stacey GandlerBrand Nourishment
Matt TurnerPatient Affordability
David LinetskyPoint-of-Care Marketing
Brenda SnowAuthentic Patient Voice
Liz KaneImpactful Strategy
Suma Ramadas, PhDMedical Affairs
Daniel SontupeMarket Access
Joey CohenMedication Adherence
Frank BurrellScientific Storytelling
Paul TheisenPatient Acquisition
Amy GilesIncreasing Engagement
YELIVA®, a proprietary, first-in-class SK2 inhibitor, was granted FDA Orphan Drug designation for the ...
Username
Email
Password
Confirm Password
Remember Me
Username or Email